Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


340B Provider Reforms Gaining Momentum In Congress

Executive Summary

House Energy & Commerce Committee recommends more oversight of hospital participation in the 340B drug discount program.


Related Content

340B Reform: US House Bills Mark The End Of The Beginning
Many 340B Providers May Not Pass On Discounts Through Contract Pharmacies – GAO
340B Legislative Reforms: Where Do We Go From Here?
The Ups and Downs Of US Drug Pricing Policy
340B Hospitals May Be Losing Transparency Debate In Congress
340B Oversight Gathering Steam In Senate; HELP Committee Plans Hearing
Should CMS Manage 340B? Sen. Hatch Raises Oversight Concerns With HHS
340B Penny Pricing, Civil Monetary Penalty Revisions On Deck In Proposed Rule
340B Providers Offer Varying Approaches To Tracking, Using Discounts At Hearing
340B Reforms: Oversight Hearing Suggests Slow, Piecemeal Approach





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts